First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment
- 1 July 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 26 (7), 774-780
- https://doi.org/10.1097/meg.0000000000000099
Abstract
Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance. The aim of this study was to assess the efficacies of tenofovir and entecavir in previously untreated CHB patients in a treatment cohort. We included CHB patients in a cohort including previously untreated HBeAg-positive and HBeAg-negative patients from 10 centers in Istanbul, Turkey. The patients were compared in terms of baseline characteristics, decrease in alanine transaminase (ALT), decrease in HBV-DNA to undetectable levels, HBeAg loss and anti-HBe development (among baseline HBeAg-positive patients), interventions to therapy because of lack of efficacy, side effects, severe side effects, and side effects that required change in treatment. The study included 121 patients who were administered tenofovir and 130 patients who were administered entecavir. The majority of patients were men, with mild to moderate histology in both treatment groups. The mean duration of follow-up was 18 and 20 months for tenofovir and entecavir, respectively. Patients receiving both drugs showed comparable rates of HBeAg loss, rates of undetectable HBV-DNA levels, rates of ALT normalization, ALT decrease, and decrease in HBV-DNA. Both drugs were well tolerated. This study shows that although the baseline characteristics did not match, tenofovir and entecavir sustained comparable virological efficacies. More patients discontinued entecavir during follow-up. Both drugs provided effective viral control, with few side effects.Keywords
This publication has 10 references indexed in Scilit:
- Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B MonoinfectionAntiviral Therapy, 2013
- Update on tenofovir toxicity in the kidneyPediatric Nephrology, 2012
- Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis BTurkish Journal of Gastroenterology, 2012
- Review article: current antiviral therapy of chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2011
- Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effectsExpert Opinion on Drug Safety, 2011
- Adverse effects of drugs in the treatment of viral hepatitisBest Practice & Research Clinical Gastroenterology, 2010
- Chronic hepatitis B: Update 2009Journal of Hepatology, 2009
- Natural history of chronic hepatitis B virus infection and long‐term outcome under treatmentLiver International, 2009
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factorsJournal of Hepatology, 2008
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006